

SCHEDULE 13G

Amendment No.  
Cytotherapeutics  
common stock  
Cusip # 232923102  
Filing Fee: Yes

Cusip # 232923102

Item 1: Reporting Person - FMR Corp. - (Tax ID: 04-2507163)  
Item 4: Commonwealth of Massachusetts  
Item 5: 6,500  
Item 6: None  
Item 7: 800,730  
Item 8: None  
Item 9: 800,730  
Item 11: 7.71%  
Item 12: HC

Cusip # 232923102

Item 1: Reporting Person - Edward C. Johnson 3d - (Tax ID:  
###-##-####)  
Item 4: United States of America  
Item 5: None  
Item 6: None  
Item 7: 800,730  
Item 8: None  
Item 9: 800,730  
Item 11: 7.71%  
Item 12: IN

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS  
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

Item 1(a). Name of Issuer:

Cytotherapeutics

Item 1(b). Name of Issuer's Principal Executive Offices:

2 Richmond Square  
Providence, RI 02906

Item 2(a). Name of Person Filing:

FMR Corp.

Item 2(b). Address or Principal Business Office or, if None,  
Residence:

82 Devonshire Street, Boston, Massachusetts 02109

Item 2(c). Citizenship:

Not applicable

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number:

232923102

Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) and the person filing, FMR Corp., is a parent holding company in accordance with Section 240.13d-1(b)(ii)(G). (Note: See Item 7).

Item 4. Ownership

(a) Amount Beneficially Owned: 800,730

(b) Percent of Class: 7.71%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote:  
6,500

(ii) shared power to vote or to direct the vote:  
None

(iii) sole power to dispose or to direct the  
disposition of: 800,730

(iv) shared power to dispose or to direct the  
disposition of: None

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of  
Another Person.

Various persons have the right to receive or the  
power to direct the receipt of dividends from, or  
the proceeds from the sale of, the common stock of  
Cytotherapeutics. No one person's interest in the  
common stock of Cytotherapeutics is more than five  
percent of the total outstanding common stock.

Item 7. Identification and Classification of the Subsidiary  
Which Acquired the Security Being Reported on By the  
Parent Holding Company.

See attached Exhibit(s) A and B.

Item 8. Identification and Classification of Members of the  
Group.

Not applicable, see attached Exhibit A.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my  
knowledge and belief, the securities referred to above  
were acquired in the ordinary course of business and  
were not acquired for the purpose of and do not have  
the effect of changing or influencing the control of  
the issuer of such securities and were not acquired in  
connection with or as a participant in any transaction  
having such purpose or effect.

Signature

After reasonable inquiry and to the best of my  
knowledge and belief, I certify that the information  
set forth in this statement is true, complete and  
correct.

February 11, 1994  
Date

/S/Arthur S. Loring  
Signature

Arthur S. Loring, Vice  
President  
Name/Title

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS  
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

Pursuant to the instructions in Item 7 of Schedule 13G, Fidelity Management & Research Company ("Fidelity"), 82 Devonshire Street, Boston, Massachusetts 02109, a wholly-owned subsidiary of FMR Corp. and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is the beneficial owner of 771,130 shares or 7.43% of the common stock outstanding of Cytotherapeutics ("the Company") as a result of acting as investment adviser to several investment companies registered under Section 8 of the Investment Company Act of 1940.

Edward C. Johnson 3d, FMR Corp., through its control of Fidelity, and the Funds each has sole power to dispose of the 771,130 shares owned by the Funds.

Neither FMR Corp. nor Edward C. Johnson 3d, Chairman of FMR Corp., has the sole power to vote or direct the voting of the Shares owned directly by the Fidelity Funds, which power resides with the Funds' Boards of Trustees. Fidelity carries out the voting of the Shares under written guidelines established by the Funds' Boards of Trustees.

Fidelity Management Trust Company, 82 Devonshire Street, Boston, Massachusetts 02109, a wholly-owned subsidiary of FMR Corp. and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934, is the beneficial owner of 29,600 shares or 0.29% of the common stock outstanding of the company as a result of its serving as investment manager of the institutional account(s).

FMR Corp., through its control of Fidelity Management Trust Company, has sole dispositive power over 29,600 Shares and sole power to vote or to direct the voting of 6,500 shares, and no power to vote or to direct the voting of 23,100 Shares of common stock owned by the institutional account(s) as reported above.

Edward C. Johnson 3d owns 34.0% of the outstanding voting common stock of FMR Corp. Mr. Johnson 3d is Chairman of FMR Corp. Various Johnson family members and trusts for the benefit of Johnson family members own FMR Corp. voting common stock. These Johnson family members, through their ownership of voting common stock, form a controlling group with respect to FMR Corp.

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS  
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

RULE 13d-1(e) AGREEMENT

The undersigned persons, on February 11, 1994, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the common stock of Cytotherapeutics at December 31, 1993.

FMR Corp.  
By /S/Arthur S. Loring  
Arthur S. Loring  
Vice President - Legal  
Edward C. Johnson 3d  
By /S/Arthur S. Loring  
Arthur S. Loring  
Under Power of Attorney  
dated 5/17/89  
On File with Schedule  
13G for  
Airborne Freight Corp.  
9/10/91

Fidelity Management & Research

Company

By /S/Arthur S. Loring

Arthur S. Loring

Sr. V.P. and General

Counsel